Noelle; Randolph

Patent Applications and Registrations

Patent applications and USPTO patent grants for Noelle; Randolph.The latest application filed is for "autoimmune disorder treatment using rxr agonists".

Company Profile

7.15.23

Noelle; Randolph - Plainfield NH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Autoimmune Disorder Treatment Using Rxr Agonists App 20220151964 - Chandraratna; Roshantha A. ; et al.	2022-05-19
Autoimmune Disorder Treatment Using Rxr Agonists App 20220117922 - Chandraratna; Roshantha A. ; et al.	2022-04-21
Autoimmune disorder treatment using RXR agonists Grant 11,246,845 - Chandraratna , et al. February 15, 2	2022-02-15
Autoimmune disorder treatment using RXR agonists Grant 11,166,927 - Chandraratna , et al. November 9, 2	2021-11-09
Autoimmune Disorder Treatment Using Rxr Agonists App 20210128504 - Chandraratna; Roshantha A. ; et al.	2021-05-06
Autoimmune Disorder Treatment Using Rxr Agonists App 20210128503 - Chandraratna; Roshantha A. ; et al.	2021-05-06
Autoimmune disorder treatment using RXR agonists Grant 10,945,976 - Chandraratna , et al. March 16, 2	2021-03-16
Autoimmune disorder treatment using RXR agonists Grant 10,695,307 - Chandraratna , et al.	2020-06-30
Treatment Of Diseases By Concurrently Eliciting Remyelination Effects And Immunomodulatory Effects Using Selective Rxr Agonists App 20200163915 - Chandraratna; Roshantha A. ; et al.	2020-05-28
Autoimmune Disorder Treatment Using Rxr Agonists App 20200155488 - Chandraratna; Roshantha A. ; et al.	2020-05-21
Autoimmune Disorder Treatment Using Rxr Agonists App 20200155489 - Chandraratna; Roshantha A. ; et al.	2020-05-21
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists Grant 10,653,650 - Chandraratna , et al.	2020-05-19
Vista Modulators For Diagnosis And Treatment Of Cancer App 20200085947 - NOELLE; Randolph	2020-03-19
Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen Grant 10,463,731 - Ahonen , et al. No	2019-11-05
Autoimmune disorder treatment using RXR agonists Grant 10,285,960 - Chandraratna , et al.	2019-05-14
Autoimmune Disorder Treatment Using Rxr Agonists App 20190125705 - Chandraratna; Roshantha A. ; et al.	2019-05-02
Autoimmune disorder treatment using RXR agonists Grant 10,201,512 - Chandraratna , et al. Feb	2019-02-12
Autoimmune Disorder Treatment Using Rxr Agonists App 20180263939 - Chandraratna; Roshantha A. ; et al.	2018-09-20
Autoimmune disorder treatment using RXR agonists Grant 10,034,845 - Chandraratna , et al. July 31, 2	2018-07-31
Autoimmune Disorder Treatment Using Rxr Agonists App 20180116985 - Chandraratna; Roshantha A. ; et al.	2018-05-03
Vista Modulators For Diagnosis And Treatment Of Cancer App 20170112929 - NOELLE; Randolph	2017-04-27
Autoimmune Disorder Treatment using RXR Agonists App 20170056348 - Chandraratna; Roshantha A. ; et al.	2017-03-02
VISTA modulators for diagnosis and treatment of cancer Grant 9,381,244 - Noelle July 5, 2	2016-07-05
Adjuvant Combinations of NKT Activator, CD40 Agent, CD40 Agonist, and Optional Antigen, the Use Through Inducing Synergistic Cellular Immunity App 20160158348 - AHONEN; Cory ; et al.	2016-06-09
Methods of promoting immunity to an infectious agent by administering CD40 agonists and alpha-galactosyl ceramide Grant 9,238,067 - Ahonen , et al. January 19, 2	2016-01-19
Autoimmune Disorder Treatment Using RXR Agonists App 20150342917 - Chandraratna; Roshantha A. ; et al.	2015-12-03
Autoimmune Disorder Treatment Using RXR Agonists App 20150196517 - Chandraratna; Roshantha A. ; et al.	2015-07-16
Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists App 20150038585 - Chandraratna; Roshantha A. ; et al.	2015-02-05
Adjuvant Combinations Comprising An Nkt Activator, A Cd40 Agent, Cd40 Agonist, And Optional Antigen, The Use Through Inducing Synergistic Cellular Immunity App 20150004163 - AHONEN; Cory ; et al.	2015-01-01
Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide Grant 8,802,098 - Ahonen , et al. August 12, 2	2014-08-12
Vista Modulators For Diagnosis And Treatment Of Cancer App 20140105912 - NOELLE; Randolph	2014-04-17
Autoimmune Disorder Treatment Using Rxr Agonists App 20130190395 - Chandraratna; Roshantha A. ; et al.	2013-07-25
Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists App 20120238623 - Chandraratna; Roshantha A. ; et al.	2012-09-20
Use Of Tlr Agonists And/or Type 1 Interferons To Alleviate Toxicity Of Tnf-r Agonist Therapeutic Regimens App 20110182847 - Noelle; Randolph ; et al.	2011-07-28
Adjuvant Combinations Of Nkt Activator, Cd40 Agonist, And Optional Antigen, The Use Through Inducing Synergistic Cellular Immunity App 20100247537 - Ahonen; Cory ; et al.	2010-09-30
CD40 receptor ligands Grant 6,472,510 - Aruffo , et al. October 29, 2	2002-10-29
Inhibiting B cell activation with soluble CD40 or fusion proteins thereof Grant 6,376,459 - Aruffo , et al. April 23, 2	2002-04-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.